These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37306623)

  • 1. Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting.
    Apple J; Shenolikar R; De Silva K; Sun P; Spira A
    Cancer Med; 2023 Jun; 12(12):13415-13425. PubMed ID: 37306623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study.
    Subramanian J; Leighl NB; Choi YL; Chou TY; Gregg J; Hui R; Marchetti A; Silvey M; Makin R; Gillespie-Akar L; Taylor A; Kahangire DA; Bailey T; Chau M; Navani N
    Lung Cancer; 2023 Jan; 175():47-56. PubMed ID: 36455396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by
    Vadagam P; Waters D; Lee I; Chen J; Tian D; Near AM; Lyle D; Vanderpoel J
    J Med Econ; 2024; 27(1):219-229. PubMed ID: 38269536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy.
    Li Z; Zhang X; Wang Y; Yu Z; Yang C; Zhou Y; Hong S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37848260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDL1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitors.
    Lasvergnas J; Fallet V; Duchemann B; Jouveshomme S; Cadranel J; Chouaïd C
    Respir Med Res; 2023 Nov; 84():101018. PubMed ID: 37302160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma.
    Chen CL; Wang ST; Liao WC; Chen CH; Tu CY; Hsia TC; Cheng WC; Chen HJ
    BMC Cancer; 2023 Sep; 23(1):847. PubMed ID: 37697233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives.
    Kato T; Casarini I; Cobo M; Faivre-Finn C; Hegi-Johnson F; Lu S; Özgüroğlu M; Ramalingam SS
    Lung Cancer; 2024 Jan; 187():107414. PubMed ID: 38088015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB-IIIA non-small cell lung cancer in Norway-a nationwide cohort study.
    Helland Å; Myklebust TÅ; Conte S; Frederiksen LE; Aarøe J; Enerly E
    Cancer Treat Res Commun; 2024; 38():100785. PubMed ID: 38190787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study.
    Molife C; Winfree KB; Bailey H; D'yachkova Y; Forshaw C; Kim S; Taipale KL; Puri T
    Adv Ther; 2023 Jul; 40(7):3135-3168. PubMed ID: 37221352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.
    Julian C; Pal N; Gershon A; Evangelista M; Purkey H; Lambert P; Shi Z; Zhang Q
    BMC Cancer; 2023 Apr; 23(1):352. PubMed ID: 37069542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance of Abundance for Mutational
    Wang Y; Liu H; Yu N; Xiang X
    Curr Oncol; 2023 Sep; 30(9):8464-8476. PubMed ID: 37754531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma.
    Esterberg E; Iyer S; Nagar SP; Davis KL; Tannir NM
    Clin Genitourin Cancer; 2024 Apr; 22(2):115-125.e3. PubMed ID: 37914609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Using a Real-World Database.
    Bhandari NR; Hess LM; He D; Peterson P
    J Natl Compr Canc Netw; 2023 Sep; 21(9):934-944.e1. PubMed ID: 37673115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy.
    Meagher MF; Minervini A; Mir MC; Cerrato C; Rebez G; Autorino R; Hampton L; Campi R; Kriegmair M; Linares E; Hevia V; Musquera M; D'Anna M; Roussel E; Albersen M; Pavan N; Claps F; Antonelli A; Marchioni M; Paksoy N; Erdem S; Derweesh IH
    Eur Urol Open Sci; 2024 May; 63():71-80. PubMed ID: 38572300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer.
    Blumenthal GM; Gong Y; Kehl K; Mishra-Kalyani P; Goldberg KB; Khozin S; Kluetz PG; Oxnard GR; Pazdur R
    Ann Oncol; 2019 May; 30(5):830-838. PubMed ID: 30796424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival Outcomes of Metastatic Non-small Cell Lung Cancer Patients With Limited Access to Immunotherapy and Targeted Therapy in a Cancer Center of a Low- and Middle-Income Country.
    Ballén DF; Carvajal-Fierro CA; Beltrán R; Alarcón ML; Vallejo-Yepes C; Brugés-Maya R
    Cancer Control; 2023; 30():10732748231189785. PubMed ID: 37537995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.
    Furqan M; Karanth S; Goyal RK; Cai B; Rombi J; Davis KL; Caro N; Saliba T
    Future Oncol; 2024 Apr; ():1-11. PubMed ID: 38629593
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC.
    Arnaoutakis K; Wan Y; Elliott J; Young M; Yin Y; Leventakos K; Lin HM; Dimou A
    Adv Ther; 2024 Jun; ():. PubMed ID: 38916812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.
    Bestvina CM; Waters D; Morrison L; Emond B; Lafeuille MH; Hilts A; Lefebvre P; He A; Vanderpoel J
    J Med Econ; 2024; 27(1):292-303. PubMed ID: 38391239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and
    Asad Zadeh Vosta Kolaei F; Cai B; Kanakamedala H; Kim J; Doban V; Zhang S; Shi M
    Front Oncol; 2022; 12():786124. PubMed ID: 35280795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.